Your browser doesn't support javascript.
loading
Open Targets: a platform for therapeutic target identification and validation.
Koscielny, Gautier; An, Peter; Carvalho-Silva, Denise; Cham, Jennifer A; Fumis, Luca; Gasparyan, Rippa; Hasan, Samiul; Karamanis, Nikiforos; Maguire, Michael; Papa, Eliseo; Pierleoni, Andrea; Pignatelli, Miguel; Platt, Theo; Rowland, Francis; Wankar, Priyanka; Bento, A Patrícia; Burdett, Tony; Fabregat, Antonio; Forbes, Simon; Gaulton, Anna; Gonzalez, Cristina Yenyxe; Hermjakob, Henning; Hersey, Anne; Jupe, Steven; Kafkas, Senay; Keays, Maria; Leroy, Catherine; Lopez, Francisco-Javier; Magarinos, Maria Paula; Malone, James; McEntyre, Johanna; Munoz-Pomer Fuentes, Alfonso; O'Donovan, Claire; Papatheodorou, Irene; Parkinson, Helen; Palka, Barbara; Paschall, Justin; Petryszak, Robert; Pratanwanich, Naruemon; Sarntivijal, Sirarat; Saunders, Gary; Sidiropoulos, Konstantinos; Smith, Thomas; Sondka, Zbyslaw; Stegle, Oliver; Tang, Y Amy; Turner, Edward; Vaughan, Brendan; Vrousgou, Olga; Watkins, Xavier.
Afiliación
  • Koscielny G; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK gautier.x.koscielny@gsk.com.
  • An P; GSK, Medicines Research Center, Gunnels Wood Road, Stevenage, SG1 2NY, UK.
  • Carvalho-Silva D; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Cham JA; Biogen, Cambridge, MA 02142, USA.
  • Fumis L; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Gasparyan R; European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Hasan S; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Karamanis N; European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Maguire M; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Papa E; European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Pierleoni A; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Pignatelli M; Biogen, Cambridge, MA 02142, USA.
  • Platt T; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Rowland F; GSK, Medicines Research Center, Gunnels Wood Road, Stevenage, SG1 2NY, UK.
  • Wankar P; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Bento AP; European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Burdett T; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Fabregat A; European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Forbes S; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Gaulton A; Biogen, Cambridge, MA 02142, USA.
  • Gonzalez CY; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Hermjakob H; European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Hersey A; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Jupe S; European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Kafkas S; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Keays M; Biogen, Cambridge, MA 02142, USA.
  • Leroy C; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Lopez FJ; European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Magarinos MP; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Malone J; Biogen, Cambridge, MA 02142, USA.
  • McEntyre J; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Munoz-Pomer Fuentes A; European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • O'Donovan C; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Papatheodorou I; European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Parkinson H; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Palka B; European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Paschall J; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Petryszak R; Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.
  • Pratanwanich N; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Sarntivijal S; European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Saunders G; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Sidiropoulos K; European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Smith T; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Sondka Z; European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Stegle O; National Center for Protein Research, No. 38, Life Science Park Road, Changping District, 102206 Beijing, China.
  • Tang YA; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Turner E; European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Vaughan B; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Vrousgou O; European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
  • Watkins X; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
Nucleic Acids Res ; 45(D1): D985-D994, 2017 01 04.
Article en En | MEDLINE | ID: mdl-27899665
ABSTRACT
We have designed and developed a data integration and visualization platform that provides evidence about the association of known and potential drug targets with diseases. The platform is designed to support identification and prioritization of biological targets for follow-up. Each drug target is linked to a disease using integrated genome-wide data from a broad range of data sources. The platform provides either a target-centric workflow to identify diseases that may be associated with a specific target, or a disease-centric workflow to identify targets that may be associated with a specific disease. Users can easily transition between these target- and disease-centric workflows. The Open Targets Validation Platform is accessible at https//www.targetvalidation.org.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Programas Informáticos / Biología Computacional / Motor de Búsqueda / Terapia Molecular Dirigida Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Nucleic Acids Res Año: 2017 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Programas Informáticos / Biología Computacional / Motor de Búsqueda / Terapia Molecular Dirigida Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Nucleic Acids Res Año: 2017 Tipo del documento: Article País de afiliación: Reino Unido